BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

12 articles for M McAuliffe

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics of L-739,010.EBI
Merck Frosst Centre For Therapeutic Research
Dioxabicyclooctanyl naphthalenenitriles as nonredox 5-lipoxygenase inhibitors: structure-activity relationship study directed toward the improvement of metabolic stability.EBI
Merck Frosst Centre For Therapeutic Research
Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.EBI
Merck Frosst Centre For Therapeutic Research
Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.EBI
Merck Frosst Centre For Therapeutic Research
 
Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enxyme inductionEBI
TBA
 
Discovery of L-740,515, a potent thienopyridine cysLT1 receptor (LTD4 receptor) antagonistEBI
TBA
 
Evolution of a series of non-quinoline leukotriene D4 receptor antagonist; synthesis and sar of benzothiazoles and thiazoles substituted benzyl alcohols as potent LTD4 antagonistsEBI
TBA
 
The discovery of L-699,392, a novel potent and orally active leukotriene D4 receptor antagonistEBI
TBA
 
The discovery of a new structural class of potent orally active leukotriene D4 antagonistsEBI
TBA
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).EBI
Merck Frosst Canada
Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.EBI
Merck Frosst Center For Therapeutic Research
A series of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair.EBI
Merck Frosst Center For Therapeutic Research